checkAd

    DGAP-Adhoc  722  0 Kommentare Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-related macular degeneration


    Carl Zeiss Meditec AG / Key word(s): Alliance

    22.12.2014 20:24

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
    Long
    93,45€
    Basispreis
    0,74
    Ask
    × 12,87
    Hebel
    Short
    107,65€
    Basispreis
    0,83
    Ask
    × 12,53
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-
    related macular degeneration


    Jena, 22 December 2014: Carl Zeiss Meditec Inc., a 100%-owned subsidiary of
    Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration
    agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past
    few years, Oraya has developed the novel low energy radiation therapy
    "Oraya
    Therapy" for wet age-related macular degeneration (wet AMD) and introduced
    it to the market.

    Under the terms of the agreement, Carl Zeiss Meditec will provide funding
    to
    Oraya for the implementation of its growth strategy over a period of up to
    two years and in turn receive rights for a participation in the company
    reaching up to a majority stake after two years. The amount of the funding
    provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this
    investment to further strengthen its role as global innovation leader in
    ophthalmology as well as its existing portfolio of solutions for diagnosis
    and therapy of eye diseases.



    Contact for investors
    Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
    Tel. +49 3641 220-116, E-Mail: investors.meditec@zeiss.com

    Press contact
    Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss
    Meditec AG
    Tel. +49 3641 220-331, E-Mail: press.meditec@zeiss.com


    22.12.2014 The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: Carl Zeiss Meditec AG
    Göschwitzer Str. 51-52
    07745 Jena
    Germany
    Phone: +49 (0)3641 220-0
    Fax: +49 (0)3641 220-112
    E-mail: investors.meditec@zeiss.com,info.meditec@zeiss.com
    Internet: www.meditec.zeiss.de
    ISIN: DE0005313704
    WKN: 531370
    Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
    in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart

    End of Announcement DGAP News-Service

    ---------------------------------------------------------------------------



    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-related macular degeneration Carl Zeiss Meditec AG / Key word(s): Alliance 22.12.2014 20:24 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer